
Sign up to save your podcasts
Or


Based on Podcast App listening data
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Given all the activity and interest recently around crypto and web3, as well as in upcoming holidays and art events, we’re re-running our episode all about NFTs (from March 2021) -- where we covered everything you need or want to know about NFTs. You can also find a curated list of resources to learn all about NFTs at future.com/nftcanon. That list, and this episode, has something for everyone -- from artists and creators and other builders to big companies and institutions or just anyone seeking to understand or even explain to others NFTs.
Here, we’ve cut through the noise around NFTs to share the signal, covering everything from:
Joining host Sonal Chokshi are Jesse Walden, now of Variant Fund, and formerly co-founder of Mediachain Labs, which was acquired by Spotify; and Linda Xie, now of Scalar Capital, and formerly an early product manager at Coinbase. As a reminder, NONE of the following should be taken as investment advice, for more important information please see a16z.com/disclosures.
[If you’re also interested in DAOs (which we touch on briefly in this episode), we just recently published a list of readings -- in the vein of our famous crypto canon resource, then NFT canon, and now DAO canon -- all about DAOs. It’s for anyone seeking to understand, build, and otherwise get involved with these “decentralized autonomous organizations” -- which represent the future of community, coordination, work, and much more… so we’ve curated resources on this list for people at different levels of interest, from dipping one’s toes in to going deep. You can find that at future.com/daocanon.]
This episode was originally released in March 2021: https://future.a16z.com/podcasts/nfts-explainer/
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
"Beyond the Meme: Ever Given, Supply Chains, and the Physical World" -- by Ryan Petersen (June 2021). Bio + essay details/ originally appeared at: https://future.a16z.com/beyond-the-meme-ever-given-supply-chains-and-the-physical-world/
More read-alouds at: https://a16z.com/tag/read-alouds/
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
There are lots of challenges in being public while trying to innovate, and limits to being a private company as well; but it's rare to see a company go public then private then back to public again. As is the case with Dell Technologies, one of the largest tech companies -- which went private 2012-2013 and then also pulled off one of the most epic mergers of all time with Dell + EMC + VMWare 2015-2016 (and which we wrote about here at the time).
Is there a method to the madness? How does one not just start, but keep, and transform, their company and business? Especially as it adapts to broader, underlying tech platform shifts. Michael Dell shares all this in his upcoming new book, Play Nice to Win: A CEO's Journey from Founder to Leader... he also, tellingly, may be one of the longest-standing founder-CEOs (37 years so far).
Because this is really a story about innovation, who decides, who judges, who does it, and where: In the markets, in public, in private; in the both the big picture and the inner detailed workings of a business beyond "cells in a spreadsheet"; and even in fighting -- or harnessing! -- narratives, whether it's the demise-of-PC or cloud wars 1.0 /2.0... And where trends like the cost paradox of cloud, and "end of cloud" edge computing, among others like AI & ML, also come in. In this special book-launch episode of the a16z Podcast with Marc Andreessen, Martin Casado, and Sonal Chokshi debate the Cloud Wars to the Company Wars (along with some behind-scenes stories and even some star wars) with Michael Dell... and whether you can really play nice to win.
image: Dell EMC World 2016/ © Dell Inc.
The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
There's no question technology played a huge role in the recent/current pandemic, including especially in the plug-and-play engineering and incredibly fast development behind the mRNA vaccines... But is there an even bigger role for the private sector, not just government, to play (and partner) when it comes to key infrastructure for future such emergencies, and even beyond?
Especially given how faulty the translation of institutional science to policy and public health measures turned out to be -- for instance, with "6 feet" of social distancing, or with fomite (vs. aerosol) transmission of COVID. And why are we still talking about the same, not specific, vaccine booster for the Delta variant? What can we learn about real-world evidence, other clinical trial approaches, and progressive (vs. binary) EUA approvals when it comes to public health emergencies? Are capabilities like genomic surveillance and mapping strains -- which require layers of technology, real time -- sitting in the right places?
In this special book-launch episode of the a16z Podcast, former FDA commissioner Dr. Scott Gottlieb -- author of the upcoming new book, Uncontrolled Spread: Why COVID-19 Crushed Us, and How We Can Defeat the Next Pandemic -- shares insights on the above, and revealing stories from behind the scenes. Do we need a new entity to manage public health through a national security lens, and is the government capable? Gottlieb debates this and other probing questions from a16z co-founder Marc Andreessen (who famously wrote "It's time to build"); a16z bio general partner Vineeta Agarwala MD, Phd (who has spoken about the trials of clinical trials, practiced medicine during the pandemic, and more); and founding a16z bio general partner Vijay Pande PhD (who, among other things, founded the distributed computing project Folding@Home which pivoted to COVID proteins).
One thing's for sure -- with this COVID crisis, we're at an inflection point between old and new technology -- whether it's in how we make vaccines, or how we apply the fields of synthetic biology and genetic epidemiology in public health response. So now's the time to look both backward, and forward, to really change things...
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
There's been a false dichotomy in technology and management lore over the past decade, between "brain" and "brawn", digital and physical, independence and interdependence, software culture versus industrial culture… or so observes Stanford Graduate School of Business lecturer, former big-company executive, and startup founder Robert Siegel in his new book, The Brains and Brawn Company: How leading organizations blend the best of digital and physical.
Whether you're an early startup or a Fortune 500 company, we live in an increasingly complex world -- which means embracing digitization is not enough. But logistics, supply chains, and infrastructure are messy, ugly, and hard. So today's leaders have to think completely differently, in terms of ecosystems; and they're often in the position of having to influence but not have control. So when and how do they assert power in an ecosystem? When do they try to shape it? When do they sit back? What to do if their channel partner suddenly changes? When do you want to stay frenemies and when do you wanna be enemies? These are just some of the hard questions companies today have to wrestle with... All boiling down to when and where to partner, when to go it alone?
So in this hallway-style discussion among Siegel and fellow Stanford b-school lecturers Jeffrey Immelt (former CEO of GE) and a16z general partner Jeff Jordan -- in conversation with host Sonal Chokshi -- the group wrestles with these questions, spinning through several different company examples such as Instacart and Stripe to Apple and Android/Google to Disney, Peloton, and others. But we talk too much about the outliers; we need to also talk more about the tools, and mindsets, that leaders of all kinds -- not just the once-in-a-generation leaders! -- can use. After all, argues Siegel, "Incumbents are not doomed and disruptors are not ordained."
The views expressed here are those of the AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Recently, a16z and the Stanford Center for Blockchain Research hosted the NFT Virtual Summit, which brought together leading thinkers and builders on the topic of NFTs, or non-fungible tokens — these tokens are enabling new creator and ownership economies to emerge. We’ve covered NFTs in other podcasts and articles, including a curated list of reading resources, and you can watch all the videos from the summit.
Today we’re sharing one of the discussions from that virtual summit (all of which were also published on our a16z Live feed) — this episode features General Partner Katie Haun chatting with Devin Finzer, cofounder of NFT marketplace OpenSea, on the topic of NFT “Use Cases, Today, and Tomorrow” — they cover the "tokenization of everything."
###
The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate "malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in preprint with The Lancet, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A "weapon" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.
So in this special 2x explainer episode of 16 Minutes (also running on the a16z Podcast), we -- Rajeev Venkayya of Takeda Pharmaceuticals, a16z bio general partner Jorge Conde, and Sonal Chokshi -- dig into what's hype/ what's real about this news, beyond the headlines and beyond the buzz. What does the data tell us, what does the current study phase mean, and what's left to get to widespread, real-world use? How does this candidate vaccine (R21 from Jenner Institute/ Oxford University) compare to the other malaria vaccine (RTS,S from GlaxoSmithKline)? How do, and don't, advances in and around COVID vaccines play here? And why has it been so hard to develop vaccines for this particular disease?
Because we also cover (as is the premise of the show) where we are on the long arc of innovation... and this is an innovation story that's been nearly a century in the making.
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
From the publisher's feed
Ranked by our users in the last 21 days

1,288 Listeners

540 Listeners

2,711 Listeners

2,193 Listeners

3,981 Listeners

221 Listeners

104 Listeners

10,100 Listeners

551 Listeners

149 Listeners

25 Listeners

292 Listeners

59 Listeners

587 Listeners

136 Listeners

102 Listeners

477 Listeners

31 Listeners

140 Listeners